TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28003251

Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in patients with combined hypertension (CH)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in patients with isolated systolic hypertension (ISH)
Number of subjects: 42
Study: 24861802

Group type: EXPERIMENTAL
Intervention: Standard care plus weekly post‐discharge breastfeeding telephone support (20-30 minutes for 4 weeks)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Standard care plus three in‐hospital professional breastfeeding support sessions (30-45 minutes each)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Standard postnatal maternity care
Number of subjects: 722
Study: 22038209

Group type: EXPERIMENTAL
Intervention: Postoperative enteral nutrition (EN)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Postoperative enteral nutrition (EN) with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Postoperative parenteral nutrition (PN) with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC)
Number of subjects: 3
Study: 19744620

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) > or = 105 pg/ml
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: BNP assessment
Number of subjects: 269
Study: 17686797

Group type: EXPERIMENTAL
Intervention: Pragmatic group: no aspiration, rapid injection and rapid withdrawal
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard of care group: slow aspiration prior to injection, slow injection and slow withdrawal
Number of subjects: 113
Study: 15262616

Group type: EXPERIMENTAL
Intervention: Randomized controlled studies (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturalistic studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence from RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catalogues for levels of evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New research agenda for naturalistic studies
Number of subjects: 0
Study: 11468761

Group type: EXPERIMENTAL
Intervention: Meta-analysis using individual patient data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAS PROC MIXED and MLwiN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian framework using BUGS
Number of subjects: 0
Study: 9753050

Group type: EXPERIMENTAL
Intervention: 100 mg/d aspirin for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7800210

Group type: EXPERIMENTAL
Intervention: 30 mg acetylsalicylic acid daily (group B)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 137
Study: 2843031

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 0
Study: 30016192

Group type: EXPERIMENTAL
Intervention: Resistance training 2 times/week (G2X)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance training 3 times/week (G3X)
Number of subjects: 45
Study: 27774990

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2.0 mg/day in cohort 1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5 mg/day in cohort 2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2.0 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mutated TET2
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pomalidomide (both doses)
Number of subjects: 96
Study: 26634922

Group type: EXPERIMENTAL
Intervention: Computerized Decision Aid (CDA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 400
Study: 23435671

Group type: EXPERIMENTAL
Intervention: gemcitabine/erlotinib followed by capecitabine
Number of subjects: 173

Group type: COMPARATOR
Intervention: capecitabine/erlotinib followed by gemcitabine
Number of subjects: 173

Group type: COMPARATOR
Intervention: non-erlotinib containing 2nd-line chemotherapy
Number of subjects: 173
Study: 22078721

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (80-90 mg/kg per day or 375 mg twice a day for infants aged 2-11 months and 625 mg twice a day for those aged 12-59 months)
Number of subjects: 1995

Group type: COMPARATOR
Intervention: First dose of oral co-trimoxazole (sulfamethoxazole 200 mg plus trimethoprim 40 mg for age 2-11 months; sulfamethoxazole 300 mg plus trimethoprim 60 mg for age 12 months to 5 years) and referral to health facility
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Oral co-trimoxazole
Number of subjects: 1995
Study: 19321570

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d) with vitamin D (16 microg/d) and calcium (700 mg/d) in women
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d) with vitamin D (16 microg/d) and calcium (700 mg/d) in men
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo with vitamin D (16 microg/d) and calcium (700 mg/d) in women
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d) and placebo
Number of subjects: 113
Study: 16765957

Group type: EXPERIMENTAL
Intervention: navMIS-DHS
Number of subjects: 78

Group type: COMPARATOR
Intervention: conv-DHS
Number of subjects: 78

Group type: COMPARATOR
Intervention: nav-DHS
Number of subjects: 78
Study: 16296368

Group type: EXPERIMENTAL
Intervention: Esmolol 0.6 mg x kg(‐1) administered immediately after HB administration
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no esmolol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (E and C)
Number of subjects: 17
Study: 11912566

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9567633

Group type: EXPERIMENTAL
Intervention: 1 mg/kg‐1 of lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5 mg/kg‐1 of urapidil
Number of subjects: 40
Study: 7882275

Group type: EXPERIMENTAL
Intervention: MFL (methotrexate, 5-FU, leucovorin)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FL (5-FU and leucovorin)
Number of subjects: 178

Group type: COMPARATOR
Intervention: F (5-FU alone)
Number of subjects: 178
Study: 1973940

Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Anxiety and Hamilton Rating Scale for Depression
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Hopkins Symptom Checklist
Number of subjects: 3000
Study: 776551

Group type: EXPERIMENTAL
Intervention: Central electrical stimulation and relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhythmic peripheral stimulation and relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular periods of relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialized somatic and psychotherapeutic methods
Number of subjects: 0
Study: 31401877

Group type: EXPERIMENTAL
Intervention: Reveal group (sFlt‐1/PlGF result known to clinicians)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Nonreveal group (sFlt‐1/PlGF result unknown)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: sFlt‐1/PlGF ratio test
Number of subjects: 370

Group type: COMPARATOR
Intervention: Clinical practice alone
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 370
Study: 28467113

Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 U/mL (Gla-300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study: 26051728

Group type: EXPERIMENTAL
Intervention: Probiotics combined with triple therapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Traditional triple therapy
Number of subjects: 132
Study: 24359618

Group type: EXPERIMENTAL
Intervention: FOCUS Harmonic Scalpel
Number of subjects: 778

Group type: COMPARATOR
Intervention: Conventional clamp-and-tie technique
Number of subjects: 778
Study: 21545917

Group type: EXPERIMENTAL
Intervention: Laparoscope training session before the clerkship (study group, n = 36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No training (control group, n = 36)
Number of subjects: 70
Study: 19423416

Group type: EXPERIMENTAL
Intervention: GNRB arthrometer
Number of subjects: 45

Group type: COMPARATOR
Intervention: KT‐1000 arthrometer
Number of subjects: 45
Study: 17090560

Group type: EXPERIMENTAL
Intervention: Early switch to oral antibiotics after 3 days of intravenous antibiotics
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard 7 day course of intravenous antibiotics
Number of subjects: 265
Study: 14982610

Group type: EXPERIMENTAL
Intervention: Formoterol (120 microg total metered dose, 90 microg delivered dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (2000 microg total metered dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11822474

Group type: EXPERIMENTAL
Intervention: 5.5% carbohydrate (CHO) solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study: 9468009

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily
Number of subjects: 0
Study: 7887144

Group type: EXPERIMENTAL
Intervention: Biotene toothpaste (lactoperoxidase-system-containing)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo toothpaste (without lactoperoxidase, KSCN, and glucose oxidase)
Number of subjects: 20
Study: 3349830

Group type: EXPERIMENTAL
Intervention: Bronchoscopic protected catheter brush (BPCB)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Telescoping catheter brush (BFW brush 10/70/90)
Number of subjects: 27
Study: 31718393

Group type: EXPERIMENTAL
Intervention: Green Dot bystander-based prevention program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 31387592

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1000 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28320789

Group type: EXPERIMENTAL
Intervention: Sustained nurse home visiting (SNHV) programme with 25 home visits from pregnancy to child age 2 years.
Number of subjects: 722

Group type: COMPARATOR
Intervention: Usual care (standard, universal Australian child and family health service).
Number of subjects: 722
Study: 25431315

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (education, participatory working groups, role models)
Number of subjects: 1649
Study: 23246796

Group type: EXPERIMENTAL
Intervention: Orally administered carotenoids
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21461326

Group type: EXPERIMENTAL
Intervention: Nasal EPAP device
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 250
Study: 18822021

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 30
Study: 16422731

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Local anaesthetics
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study: 12631530

Group type: EXPERIMENTAL
Intervention: LPD group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 3

Group type: COMPARATOR
Intervention: RPD group
Number of subjects: 3
Study: 10934071

Group type: EXPERIMENTAL
Intervention: Tuberculosis incidence in the homeless population
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Risk factors for tuberculosis
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Transmission patterns
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Control measures
Number of subjects: 2774
Study: 9360530

Group type: EXPERIMENTAL
Intervention: Hypogonadal state (induced by leuprolide)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Eugonadal state (saline injections)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High dose testosterone (testosterone enanthate, 3 mg/kg.week)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stanozolol (0.1 mg/kg.day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hypogonadal state vs Eugonadal state
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High dose testosterone treatment
Number of subjects: 5
Study: 10146806

Group type: EXPERIMENTAL
Intervention: Writing about personal traumatic experiences
Number of subjects: 41

Group type: COMPARATOR
Intervention: Writing about non-traumatic topics
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Emotional inhibition levels
Number of subjects: 41
Study: 2865766

Group type: EXPERIMENTAL
Intervention: Estrogen replacement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Estrogen replacement and Placebo
Number of subjects: 10
Study: 31536041

Group type: EXPERIMENTAL
Intervention: Vinpocetine (2 mg/kg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vinpocetine
Number of subjects: 87
Study: 29724300

Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 48

Group type: COMPARATOR
Intervention: paclitaxel only
Number of subjects: 48
Study: 27512103

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 µg/kg per minute)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Low-dose nesiritide (0.005 μg/kg per minute without bolus)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 24784909

Group type: EXPERIMENTAL
Intervention: Stand group (n = 29)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Step group (n = 31)
Number of subjects: 60
Study: 21903032

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 6 weeks (T0)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paroxetine 30-50 mg/d for 6 weeks (T1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment responders
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo dose escalation
Number of subjects: 22
Study: 21034206

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (grief therapy)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 122
Study: 19019649

Group type: EXPERIMENTAL
Intervention: Ambu laryngeal mask
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Solus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Soft Seal
Number of subjects: 200
Study: 16183994

Group type: EXPERIMENTAL
Intervention: Double embryo transfer
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Subsequent transfer of a frozen embryo
Number of subjects: 4

Group type: COMPARATOR
Intervention: Single embryo transfer
Number of subjects: 4
Study: 12149523

Group type: EXPERIMENTAL
Intervention: Nurse practitioner led care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Doctor led care
Number of subjects: 80
Study: 11574732

Group type: EXPERIMENTAL
Intervention: Immobilized polymyxin B fibers (PMX-F)
Number of subjects: 98
Study: 9142020

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Number of subjects: 77
Study: 8273216

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined Group A + B (no treatment control)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment control (Group B)
Number of subjects: 29
Study: 3551837

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 38
Study: 29385232

Group type: EXPERIMENTAL
Intervention: Glutathione-PEGylated liposomal methylprednisolone (2B3-201)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free methylprednisolone (active comparator)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28045799

Group type: EXPERIMENTAL
Intervention: Brief communication skills training (CST) program based on cognitive behavioral therapy (CBT)
Number of subjects: 206
Study: 26591680

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) therapy including Daoyin, Tuina, and acupotomology
Number of subjects: 120

Group type: COMPARATOR
Intervention: Milwaukee brace
Number of subjects: 120
Study: 23925758

Group type: EXPERIMENTAL
Intervention: Cocoa consumption for 30 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cocoa consumption
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive measures (Mini‐Mental State Examination and Trail Making Test A and B)
Number of subjects: 60
Study: 22008443

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (three cycles of 30 seconds of ischemia and 30 seconds of reperfusion)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no ischemic postconditioning)
Number of subjects: 80
Study: 18055072

Group type: EXPERIMENTAL
Intervention: EP HIV-1090 vaccine (0.5, 2.0, or 4.0mg doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 16933590

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 115

Group type: COMPARATOR
Intervention: Zuclopenthixol-depot
Number of subjects: 115
Study: 12892853

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy plus enriched treatment‐as‐usual (CBT‐ETAU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Enriched treatment‐as‐usual only (ETAU)
Number of subjects: 42
Study: 11192477

Group type: EXPERIMENTAL
Intervention: etodolac 400mg in solution, given as a single dose over 1 minute
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: etodolac 400mg in divided doses over 30 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: etodolac 400mg in divided doses over 90 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed absorption (not specified dosage)
Number of subjects: 24
Study: 9183496

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented preterm formula (NF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular preterm formula (F)
Number of subjects: 40
Study: 1285663

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg orally between the 5th and 7th day post MI, sustained until the end of the study.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg capsules t.i.d. started between days 5 and 7 post MI.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment according to the ICCU routine.
Number of subjects: 30
Study: 29283975

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28742913

Group type: EXPERIMENTAL
Intervention: Mobile health intervention for infant safe sleep practices
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Nursing quality improvement intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control mobile health intervention for breastfeeding
Number of subjects: 1600
Study: 26226166

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 4 g
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24217863

Group type: EXPERIMENTAL
Intervention: Expressive writing about life goals
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control topic (review of a recent book or film)
Number of subjects: 46
Study: 21364957

Group type: EXPERIMENTAL
Intervention: 7-day diet/exercise intervention (low saturated fat, low added sugar, high fiber diet; exercise: cycling, six sessions lasting 40-45 min/session at 65% VO2 max)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 7-day diet/exercise intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 37
Study: 18308795

Group type: EXPERIMENTAL
Intervention: 100 mg 5-HTP with CBD
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg 5-HTP with CBD
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 300 mg 5-HTP with CBD
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5-HTP with CBD
Number of subjects: 15
Study: 16608859

Group type: EXPERIMENTAL
Intervention: Revascularization within 7 days
Number of subjects: 13451

Group type: EXPERIMENTAL
Intervention: Revascularization in France and USA
Number of subjects: 13451

Group type: EXPERIMENTAL
Intervention: Patients' propensity for revascularization based on clinical factors
Number of subjects: 13451

Group type: COMPARATOR
Intervention: Country-level factors
Number of subjects: 13451
Study: 14616254

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 microg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 microg)
Number of subjects: 101
Study: 10790551

Group type: EXPERIMENTAL
Intervention: Micro-LC (three 2-mm trocars and one 10-mm trocar)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) (two 10-mm and two 5-mm trocars)
Number of subjects: 26
Study: 8988064

Group type: EXPERIMENTAL
Intervention: 10 mg intramuscular ketorolac
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular ketorolac
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 60 mg intramuscular ketorolac
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 90 mg intramuscular ketorolac
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study: 1596720

Group type: EXPERIMENTAL
Intervention: Evening primrose oil; treatment improved fatty acid profiles towards normal; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study: 3901218

Group type: EXPERIMENTAL
Intervention: Biostim (2 mg/day for the first month, 1 mg/day for the second and third months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Biostim
Number of subjects: 110